Oncology Live®
Vol.27/No.3
Volume: 27
Vol.27/No.2
Volume: 27
Issue: 2
Vol.27/No.1
Volume: 27
Issue: 1
Vol.26/No.12
Volume: 26
Issue: 12
Vol.26/No.11
Volume: 26
Issue: 11
Vol.26/No.10
Volume: 26
Vol. 26/No. 9
Volume: 26
Issue: 9
Vol. 26/No. 8
Volume: 26
Issue: 8
Vol. 26/No. 7
Volume: 26
Issue: 7
Vol. 26/No. 6
Volume: 26
Issue: 6
Vol. 26/No. 5
Volume: 26
Issue: 5
Vol. 26/No. 4
Volume: 26
Issue: 4
Vol. 26/No. 3
Volume: 26
Issue: 3
Vol. 26/No. 2
Volume: 26
Issue: 2
Vol. 26/No. 1
Volume: 26
Issue: 1
Vol. 25 No. 16
Volume: 25
Issue: 16
Vol. 25/No. 15
Volume: 25
Issue: 15
Vol. 25/No. 14
Volume: 25
Issue: 14
Vol. 25/No. 13
Volume: 25
Issue: 13
Vol. 25/No. 12
Volume: 25
Issue: 12
Vol. 25/No. 11
Volume: 25
Issue: 11
Vol. 25/No. 10
Volume: 25
Issue: 10
Vol. 25 No. 9
Volume: 25
Issue: 9
Vol. 25 No. 8
Volume: 25
Issue: 08
Vol. 25 No. 7
Volume: 25
Issue: 7
Vol. 25 No. 6
Volume: 25
Issue: 6
Vol. 25 No. 5
Volume: 25
Issue: 5
Vol. 25 No. 4
Volume: 25
Issue: 4
Vol 25/No. 3
Volume: 25
Issue: 3
Vol. 25 No. 2
Volume: 25
Issue: 2
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5